ArticleLeukemia2012
How to manage children and young adults with myeloproliferative neoplasms.
Article in Leukemia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 46 citations in OpenAlex.
- Adolescent and Young Adult versus Older Adult Philadelphia-Negative Myeloproliferative Neoplasms: A Single-Center Experience from the MENA Region.Journal of blood medicine · 2026Article
- Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature.British journal of haematology · 2024Review
- Complete resolution of primary myelofibrosis in an infant with steroids and hydroxyurea.BMJ case reports · 2023Article
- Clinical features associated with thrombotic events in children with myeloproliferative neoplasms.American journal of hematology · 2022Article
- Essential Thrombocythemia in Children and Adolescents.Cancers · 2021Review
- Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.Annals of hematology · 2021Review
- Polycythemia vera as a rare cause of hypertension in a young man.BMJ case reports · 2021Article
- Essential Thrombocythemia in Children: A Retrospective Study.Journal of hematology · 2021Article
- Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia.Pediatric blood & cancer · 2021Article
- Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults.Current hematologic malignancy reports · 2020Review
- Children and Adolescents with Chronic Myeloproliferative Neoplasms: Still an Unmet Biological and Clinical Need?HemaSphere · 2019Article
- Secondary severe thrombocytosis in a patient who underwent splenectomy due to hereditary spherocytosis and its treatment using hydroxyurea.The Pan African medical journal · 2019Article
- Article
- Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome.BMJ case reports · 2017Article
- Essential Thrombocythemia in a Two-year-old Child, Responsive to Hydroxyurea but Not Aspirin.Oman medical journal · 2017Article
- Reply to the Letter by Bennett JM, Ann Lab Med 2015;35:542-3.Annals of laboratory medicine · 2016Article
- Primary thrombocytosis in children.Haematologica · 2014Review
- Personalized management of essential thrombocythemia-application of recent evidence to clinical practice.Leukemia · 2013Review
- Essential thrombocythemia: a rare disease in childhood.Revista brasileira de hematologia e hemoterapia · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
On the basis of my personal clinical and research experience and validated by the current literature, my approach to the management of pediatric (age <18 years) and young patients (age <40 years) with classic myeloproliferative neoplasms is presented by focusing on diagnosis, patient communication, risk stratification and therapy. The WHO-2008 diagnostic criteria are recommended, even though in children suspected with essential thrombocythemia (ET), a specific set of diagnostic features may be required. Patient communication includes information on natural history, genetic abnormalities and counseling in all women of child-bearing age. The main challenge in children and young adults with ET and polycythemia vera (PV) is to avoid recurrence of major thrombosis by selecting those patients who ultimately can benefit from cytotoxic and antithrombotic therapy without increasing the incidence of drug-induced side effects. In asymptomatic low-risk patients no therapy is prescribed while in high-risk low-dose aspirin, hydroxyurea and interferon-alpha are my first line drugs. My first decision when considering treatment of a young patient with primary myelofibrosis (PMF) or post-PV or post ET-myelofibrosis, is whether he/she qualifies for bone marrow allotransplantation. In the remaining young PMF patients palliative therapy or experimental drugs are considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.